Quattro Financial Advisors’s Moderna MRNA Stock Holding History

Quattro Financial Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.75M	Hold	25,000	–	–	0.37%	54
2026 Q1	$1.27M	Hold	25,000	–	–	0.38%	53
2025 Q4	$737K	Hold	25,000	–	–	0.22%	60
2025 Q3	$646K	Hold	25,000	–	–	0.2%	62
2025 Q2	$690K	Hold	25,000	–	–	0.24%	55
2025 Q1	$709K	Sell	25,000 -59,600	-70%	-$2.11M	0.24%	57
2024 Q4	$3.44M	Buy	84,600 +22,500	+36%	+$1.08M	0.89%	25
2024 Q3	$3.63M	Sell	62,100 -25,000	-29%	-$2.3M	1.02%	27
2024 Q2	$10.3M	Hold	87,100	–	–	2.7%	11
2024 Q1	$9.28M	Buy	87,100 +87,001	+87,880%	+$8.77M	2.64%	11
2023 Q4	$7.7M	Sell	99 -57,201	-100%	-$4.81M	2.66%	10
2023 Q3	$5.92M	Buy	57,300 +37,300	+187%	+$4.16M	2.58%	12
2023 Q2	$2.43M	Buy	20,000 +10,000	+100%	+$1.33M	0.97%	27
2023 Q1	$1.54M	Buy	10,000 +5,000	+100%	+$825K	0.63%	33
2022 Q4	$898K	Sell	5,000 -5,000	-50%	-$818K	0.36%	45
2022 Q3	$1.18M	Hold	10,000	–	–	0.47%	35
2022 Q2	$1.43M	Buy	+10,000	New	+$1.43M	0.49%	36

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Quattro Financial Advisors's MRNA Position: Q2 2026 in Review

Quattro Financial Advisors held its Moderna (MRNA) position steady in Q2 2026 at 25,000 shares worth $1.75M. The position accounts for 0.37% of the portfolio, ranked #54.

Quattro Financial Advisors first reported a position in MRNA in Q2 2022 and has held it in 17 quarters since. The position peaked at $10.3M in Q2 2024. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Quattro Financial Advisors held 25,000 shares of Moderna worth $1.75M as of Q2 2026.
Quattro Financial Advisors left its Moderna share count unchanged in Q2 2026.
Moderna made up 0.37% of Quattro Financial Advisors's portfolio in Q2 2026, its #54 holding.
Quattro Financial Advisors first reported a position in Moderna in Q2 2022 and has held it in 17 quarters since.
Quattro Financial Advisors's Moderna position peaked at $10.3M in Q2 2024.
780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Quattro Financial Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.